Biotech Valuation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation

CRSP 51.08

+0.7%

11:41 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (2716)	1/29/2001 8:00:10 PM
From: aknahow	Read Replies (3) of 52153

Any information, pro or con on Onyx Pharmaceutical (onxx) would be appreciated. I am specifically interested in what anyone know about the drug discussed in todays release. <<<"Onyx Pharmaceuticals is engaged in the discovery and development of novel targeted, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing CI-1042 as its lead product. CI-1042 is a therapeutic>>>" Never heard of Onyx before today. The drug is being developed with Pfizer and is in P III. tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and lyse (burst) cancer cells that have abnormal p53 pathway function while sparing normal cells that have functioning p53. Derangements in the p53 protein pathway are the most common genetic abnormalities in human cancer. CI-1042 is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of additional cancer indications.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next